Top

04-04-2024 | Liraglutide | Original Article

Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery

Authors: Martha Patricia Sánchez Muñoz, José Daniel Reyes Blandón, Ileana Susana Camba Gutierrez, Carlos Manuel Moreno Mendoza, Ma. Soledad Aldana Aguiñaga, César Alberto Ortiz Orozco

Published in: Updates in Surgery

Abstract

Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain better outcomes and less morbidity for bariatric surgery. Therefore, we evaluated the effectiveness of GLP-1 analogue Liraglutide in preoperative weight loss. We performed a single-center, quasi-experimental prospective study. Eligible participants were adults in preoperative management for bariatric-metabolic surgery with body-mass index ≥ 48 kg/m². All patients were assigned liraglutide treatment, with an initial dose of 0.6 mg subcutaneous per day, the dose was increased each week until reaching 3.0 mg for 12 weeks. Weight loss and body composition were evaluated monthly using bioelectric impedance (BIA) (InBody 770 Scale®). We analyzed data using descriptive statistics, central tendency measures and dispersion for quantitative variables and absolute and relative frequencies for qualitative variables. A total of 37 individuals were included in this study, 28 (76%) were female and 9 (24%) were males, with an average age of 44 years. About the BMI, 19 patients (51%) had a BMI > 50 kg/m², 10 (27%) > 40 kg/m² and 8 (22%) > 60 kg/m²; with a total average BMI of 56.04 kg/m². The initial weight was 147.4 ± 14.9 kg which decreased to 139.3 ± 16.8 kg; after 3 months of liraglutide administration. A total of 35 patients had some degree of weight loss (94.6%), while 2 (5.40%) had no weight changes. The total weight loss was 5.50% at 3 months of liraglutide treatment. Liraglutide could be an effective adjuvant therapy for preoperative weight loss in patients living with severe obesity.

Duarte RM (2015) Obesidad y sobrepeso una epidemia mundial. Rev Med Hondur 83:5–7

Organization for Economic Co-operation and Development (OECD) Obesity Update 2012. Disponible en http://www.oecd.org/health/49716427.pdf. Accessed 12 Aug 2022

Rtveladze K, Marsh T, Barquera S et al (2014) Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutr 17(1):233–239. https://doi.org/10.1017/S1368980013000086CrossRefPubMed

Barrera-Cruz A, Rodríguez-González A, MolinaAyala MA (2013) Escenario actual de la obesidad en Mexico. Rev Med Inst Mex Seguro Soc 51(3):292–299PubMed

Nguyen NT, Brethauer SA, Morton JM, Ponce J, Rosenthal RJ (2020) The ASMBS textbook of bariatric surgery. Springer, pp 83–88 (Chap 7, Renée M. Tholey, David S. Tichansky, ISBN : 978-3-030-27020-9)CrossRef

Yanovski SZ, Yanovski JA (2014) Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311(1):74–86. https://doi.org/10.1001/jama.2013.281361CrossRefPubMedPubMedCentral

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2017) Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes 23 management algorithm – 2017 executive summary. Endocr Pract [Internet] 23(2):207–238CrossRefPubMed

Carter J, Chang J, Birriel TJ et al (2021) ASMBS position statement on preoperative patient optimization before metabolic and bariatric surgery. Surg Obes Relat Dis 17(12):1956–1976. https://doi.org/10.1016/j.soard.2021.08.024CrossRefPubMed

Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11–22. https://doi.org/10.1056/NEJMoa1411892CrossRefPubMed

10.

World Medical Association (2001) World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Org 79(4):373–374PubMedCentral

11.

Tallarida RJ, Murray RB (1987) Chi-square test. In: Manual of pharmacologic calculations. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4974-0_43

12.

Zimmerman DW (1987) Comparative power of student T test and Mann-Whitney U test for unequal sample sizes and variances. J Exp Educ 55(3):171–174. https://doi.org/10.1080/00220973.1987.10806451CrossRef

13.

Sun Y, Liu B, Smith JK, Correia MLG, Jones DL, Zhu Z, Taiwo A, Morselli LL, Robinson K, Hart AA, Snetselaar LG, Bao W (2020) Association of preoperative body weight and weight loss with risk of death after bariatric surgery. JAMA Netw Open 3(5):e204803. https://doi.org/10.1001/jamanetworkopen.2020.4803. (PMID: 32407504; PMCID: PMC7225906)CrossRefPubMedPubMedCentral

14.

Santo MA, Riccioppo D, Pajecki D, Cleva RD, Kawamoto F, Cecconello I (2014) Preoperative weight loss in super-obese patients: study of the rate of weight loss and its effects on surgical morbidity. Clinics (Sao Paulo) 69(12):828–834. https://doi.org/10.6061/clinics/2014(12)07. (PMID: 25627995; PMCID: PMC4286674)CrossRefPubMed

15.

Cassie S, Menezes C, Birch DW, Shi X, Karmali S (2011) Effect of preoperative weight loss in bariatric surgical patients: a systematic review. Surg Obes Relat Dis 7(6):760–767. https://doi.org/10.1016/j.soard.2011.08.011CrossRefPubMed

16.

Orlando G, Gervasi R, Luppino IM et al (2014) The role of a multidisciplinary approach in the choice of the best surgery approach in a super-super-obesity case. Int J Surg 12(Suppl 1):S103–S106. https://doi.org/10.1016/j.ijsu.2014.05.037CrossRefPubMed

17.

Organización Mundial de la Salud (OMS). Recomendaciones Mundiales sobre Actividad Física para la Salud. Geneva: OMS; 2010 [citado 2019 oct 23].Disponible en: http:// scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Recomendaciones+Mundiales+sobre+actividad+F?sica

18.

Simón B, Lucía H-B, Belem T-V, Teresa S, Ismael C-N, Juan R-D (2022). Obesidad en México, prevalencia y tendencias en adultos. Ensanut 2018–19. Salud pública Méx [revista en la Internet]. 2020 Dic [citado 2023 Feb 02] ; 62(6): 682–692. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342020000600682&lng=es. Epub 15-Ago-2022. https://doi.org/10.21149/11630.

19.

Wilmington R, Ardavani A, Simenacz A et al (2024) Liraglutide 3.0 mg (Saxenda©) for weight loss and remission of pre-diabetes. real-world clinical evaluation of effectiveness among patients awaiting bariatric surgery. Obes Surg 34:286–289. https://doi.org/10.1007/s11695-023-06895-7CrossRefPubMed

20.

O’Neil PM, Birkenfeld AL, McGowan B et al (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392(10148):637–649. https://doi.org/10.1016/S0140-6736(18)31773-2CrossRefPubMed

21.

Astrup A, Carraro R, Finer N et al (2012) Safety, tolerabilityand sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [published correction appears in Int J Obes (Lond). 2012 Jun;36(6):890] [published correction appears in Int J Obes (Lond). 2013 Feb;37(2):322]. Int J Obes (Lond) 36(6):843–854. https://doi.org/10.1038/ijo.2011.158CrossRefPubMed

22.

Mehta A, Marso SP, Neeland IJ (2017) Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 3(1):3–14. https://doi.org/10.1002/osp4.84CrossRefPubMed

23.

Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. JAMA 327(2):138–150. https://doi.org/10.1001/jama.2021.23619CrossRefPubMedPubMedCentral

24.

Seo YG (2021) Side effects associated with liraglutide treatment for obesity as well as diabetes. J Obes Metab Syndr 30(1):12–19. https://doi.org/10.7570/jomes20059.PMID:33071241;PMCID:PMC8017323CrossRefPubMed

Title: Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery
Authors: Martha Patricia Sánchez Muñoz
José Daniel Reyes Blandón
Ileana Susana Camba Gutierrez
Carlos Manuel Moreno Mendoza
Ma. Soledad Aldana Aguiñaga
César Alberto Ortiz Orozco
Publication date: 04-04-2024
Publisher: Springer International Publishing
Keywords: Liraglutide
Obesity
Obesity
Published in: Updates in Surgery
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-024-01828-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content